68Ga-FAPI clinical trials
68Ga-FAPI is named as an intervention in 4 current clinical trials in our China and Netherlands registers. 4 are recruiting patients now. The most common phase is Phase 1. The sponsor with the most trials is Peking Union Medical College Hospital (2). The most-studied condition is Pulmonary Fibrosis.
How 68Ga-FAPI works
All drug targets →- Prostate cancerPhase 2
- Breast cancerPhase 1
- Colorectal cancerPhase 1
- Non-small cell lung carcinomaPhase 1
- Pancreatic ductal adenocarcinomaPhase 1
- Neuroendocrine neoplasmEarly phase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4650356, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for 68Ga-FAPI
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of 68Ga-FAPI
4 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Assessment of the Value of FAPI and FDG-PET-CT in Diagnosis of Acute Phase Peyronie's Disease
NCT07903987 · ClinicalTrials.gov ↗ · Peyronie's Disease
|
Phase 4 | Recruiting | University Medical Center Groningen | Netherlands |
|
Analyse of Inflammatory Activity of Sjögren's Syndrome on 68Ga-FAPI PET-CT
NCT07062523 · Sjogren's Syndrome
|
Phase 1/2 | Recruiting | Peking Union Medical College Hospital | China |
|
Head-to-head Comparison of Diagnosis Value of Pulmonary Fibrosis on 68Ga-FAPI-04 and 18F-FDG PET-CT
NCT05121779 · ClinicalTrials.gov ↗ · Pulmonary Fibrosis
|
Phase 1 | Recruiting | Peking Union Medical College Hospital | China |
|
68Ga-FAPI PET/CT in Malignant Tumors
NCT05034146 · ClinicalTrials.gov ↗ · Fibroblast Activation Protein Inhibitor, PET/CT, Malignant Neoplasm
|
Not applicable | Recruiting | Zhongnan Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with 68Ga-FAPI
6 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Peking Union Medical College Hospital | 2 |
| Zhongnan Hospital | 1 |
| University Medical Center Groningen | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 3 |
| Clinical trials in Netherlands | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about 68Ga-FAPI trials
How many clinical trials are testing 68Ga-FAPI?
4 current trials in our China and Netherlands registers name 68Ga-FAPI as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are 68Ga-FAPI trials recruiting patients?
Yes. 4 of the 4 trials are recruiting: 3 with sites in China and 1 with sites in Netherlands. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors 68Ga-FAPI clinical trials?
Peking Union Medical College Hospital (2), Zhongnan Hospital (1) and University Medical Center Groningen (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how 68Ga-FAPI works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how 68Ga-FAPI works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists 68Ga-FAPI (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.